The GPSM1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line, designed for loss-of-function studies of the GPSM1 gene. This product offers a genetically heterogeneous pool of edited cells, avoiding the biases of single-cell cloning while enabling robust population-level analyses. The targeted disruption of GPSM1 by CRISPR/Cas9 technology provides a versatile model to examine its roles in signal transduction, mitotic spindle orientation, and asymmetric cell division within a cancer epithelial background.
HT29 is a widely used human colorectal adenocarcinoma line with epithelial morphology, originally isolated from a primary tumor. These cells carry mutations in APC and TP53 and retain the capacity to differentiate, making them a relevant system for colorectal cancer biology, drug response profiling, and studies of tumor progression. Incorporating the GPSM1 knockout into HT29 allows direct investigation of how this gene influences hallmark cancer phenotypes such as proliferation, polarity, and differentiation.
GPSM1 encodes a guanine nucleotide dissociation inhibitor that specifically binds G??i/o subunits (GNAI1, GNAI2, GNAI3, GNAO1), maintaining them in an inactive state and modulating GPCR signaling cascades. In mitotic spindle orientation, GPSM1 acts upstream of GPSM2 (LGN), which recruits NuMA and dynein to link astral microtubules to the cell cortex, ensuring correct division plane positioning. Additionally, GPSM1-mediated G protein regulation may crosstalk with the Hippo pathway, influencing the phosphorylation and nuclear localization of YAP1/TAZ transcriptional co-activators. Consequently, loss of GPSM1 disrupts these macromolecular complexes and downstream effectors, including TEAD-mediated transcription, thereby altering cell fate decisions.
In the context of colorectal cancer, GPSM1-dependent control of spindle orientation and Hippo signaling is implicated in maintaining epithelial architecture and stem cell dynamics. HT29 cells deficient in GPSM1 provide a platform to study how extracellular stimuli such as LPA and S1P, acting through their cognate GPCRs, influence tumor cell behavior. The polyclonal knockout model mirrors the heterogeneity observed in tumors, facilitating research into GPSM1??s contribution to processes like metastasis, drug resistance, and cancer stem cell self-renewal without confounding clonal effects.
These polyclonal knockout cells are compatible with a broad array of experimental techniques, including western blotting and immunofluorescence for target validation, flow cytometry for cell cycle and apoptosis analyses, colony formation and migration/invasion assays for functional phenotyping, and RNA-seq for transcriptomic characterization. Co-immunoprecipitation can be employed to map altered GPSM1 interactomes, while YAP/TAZ reporter assays directly probe Hippo pathway activity. The model is particularly well-suited for dissecting GPCR?CG??i?CGPSM1?CGPSM2?CNuMA?Cdynein signaling axes, investigating asymmetric cell division, and identifying therapeutic targets in colorectal cancer. For additional technical information, please contact Ascent Research.
